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Abstract
Guidelines and recommendations developed and/or endorsed by the American College of
Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not
to dictate the care of a particular patient. The ACR considers adherence to these guidelines and
recommendations to be voluntary, with the ultimate determination regarding their application to be
made by the physician in light of each patient’s individual circumstances. Guidelines and
recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee
any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are
subject to periodic revision as warranted by the evolution of medical knowledge, technology, and
practice.
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Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth
birthday and persists for at least 6 weeks with other known conditions excluded (1). JIA is
one of the more common chronic diseases of childhood, with a prevalence of approximately
1 per 1,000 (2,3). JIA often persists into adulthood and can result in significant long-term
morbidity, including physical disability (4---9). Recent major advances in treatment have
greatly improved short- and medium-term outcomes for children with JIA (10---17), yet no
validated guidelines offer recommendations for the treatment of JIA.
To develop recommendations for the safest and most effective treatment of JIA on behalf of
the American College of Rheumatology (ACR), we applied the established Research and
Development /University of California at Los Angeles (RAND/UCLA) Appropriateness
Method (18) to derive recommendations that are as evidence based as possible. Similar
methods were used recently in the development of the ACR recommendations for the use of
disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (19) and the
management of glucocorticoid-induced osteoporosis (20). We sought to give our
recommendations additional strength by following the principles of the Appraisal of
Guidelines for Research and Evaluation instrument (21), a framework designed specifically
to assess the quality of clinical practice guidelines, including the methods used for their
development and the content of the final recommendations.
Our effort focused on the initiation and safety monitoring of therapeutic agents in the
treatment of JIA, including nonsteroidal antiinflammatory drugs (NSAIDs), intraarticular
glucocorticoid injections, nonbiologic DMARDs, biologic DMARDs, and systemic
glucocorticoids for the treatment of the systemic features of systemic arthritis. The
indications for systemic glucocorticoids for the treatment of synovitis were not considered,
owing to a lack of published evidence. We did not consider all ILAR categories of JIA
individually and instead grouped children with JIA into distinct “treatment groups” (see
Materials and Methods). We did not consider the economic costs of JIA or its treatment for
two reasons: first, too few economic analyses of JIA exist to permit conclusions; second, the
RAND/UCLA Appropriateness Method specifically does not consider cost implications
(18). These recommendations were developed with international input and are intended to
inform and benefit health care providers caring for children with JIA throughout the world.
Many recommendations fall outside the present bounds of regulatory agency---approved
labeling, but reflect common and widely accepted practices in the field.
The products of this project are termed “recommendations” rather than guidelines in order to
reflect their nonprescriptive nature. They are meant to function as a reference and do not
serve as a substitute for individualized patient assessment and clinical decision making,
especially when conducted by specialist clinicians familiar with the treatment of JIA.
Importantly, these recommendations are not intended to limit health care coverage for
children with JIA.
MATERIALS AND METHODS
RAND/UCLA Appropriateness Method overview
The RAND/UCLA Appropriateness Method was originally developed to help determine
when the benefits of a medical intervention outweigh the risks (18) with the understanding
that the published literature often does not provide evidence at the level of detail required to
guide decisions in everyday clinical practice. This method relies upon the efforts of two
distinct groups of participants: the Core Expert Panel (CEP) and the Task Force Panel
BEUKELMAN et al. Page 2













(TFP). Our CEP was composed of experienced pediatric rheumatologists from the US,
Canada, and Europe who are among the world’s leaders in the investigation of the treatment
of JIA. The TFP contained internationally recognized pediatric rheumatology clinicians and
researchers from the US, Canada, and Europe; an advanced practice pediatric rheumatology
nurse; a general pediatrician with expertise in evidence-based medicine; and a patient
representative, i.e., a parent of a child with JIA who has broad experience in JIA and family
treatment preferences.
The initial step was a systematic review of the literature, which was then used by the CEP to
prepare a summary report of the latest scientific evidence. Concurrently, the CEP prepared a
comprehensive list of clinical scenarios (or potential indications) for each medical
intervention of interest to be addressed by the recommendations. The scenarios categorized
hypothetical patients using all possible combinations of key clinical parameters, such as
disease activity and prognostic features, relevant to the decision process. The evidence
report and the clinical scenarios were presented to the TFP for their review.
Evaluation of the scenarios by the TFP led directly to the recommendations for each medical
intervention. In the first round of voting, the TFP anonymously and independently rated the
appropriateness of the medical interventions in the clinical scenarios based on the scientific
evidence and their best clinical judgment. Differences in opinion from the first round of
voting were discussed at a face-to-face meeting, followed by a second rating of the clinical
scenarios. The final ratings were compiled and assessed by the CEP and no significant
discrepancies were identified. Finally, the ratings were used by the CEP to create
recommendations from the clinical scenarios.
Scope of recommendations
These recommendations cover the indications and safety monitoring for the use of NSAIDs,
intraarticular glucocorticoid injections, nonbiologic DMARDs, biologic DMARDs, and
systemic glucocorticoids for the treatment of the systemic features of systemic arthritis. In
contrast to prior ACR recommendations, the scope of this project was not explicitly
established by the ACR, but rather by the CEP members. An exhaustive list of broad
potential topics for inclusion was constructed by the principal investigator and reviewed and
revised by 3 other CEP members. The resultant list of 23 potential topics for consideration
was distributed to all CEP members. Using a modified Delphi process via electronic mail,
the list of topics was prioritized and gradually shortened until it was deemed feasible in the
time allotted to the project. As a result, several relevant topics were necessarily omitted.
Medication contraindications and intolerance were not considered. We suggest referring to
the 2008 ACR recommendations for the use of DMARDs in rheumatoid arthritis (19) for
general guidance about medication contraindications. Tapering or discontinuation of
medications for patients with inactive disease was also not considered. Only the most
relevant and frequently used agents within each medication class were included, as
determined using a structured iterative process via electronic mail with repeated revisions to
the proposed list until it was accepted by all CEP members. Agents not widely commercially
available for the treatment of JIA at the time of the literature search (e.g., canakinumab,
rilonacept, tocilizumab) were excluded. The indications for systemic glucocorticoids for the
treatment of synovitis were not considered, owing to a lack of published evidence. The
treatment of uveitis, enthesitis, and macrophage activation syndrome was not considered.
Systematic literature review
The systematic literature review was restricted to publications available in Medline. Briefly,
we searched using PubMed for articles in English, with abstracts, and published from 1966
to the present. The final search strategy, developed in consultation with a virtual reference
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librarian, is shown in Supplementary Appendix A (available in the online version of this
article at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658). We performed
the final search on March 3, 2009, and identified 756 articles for further consideration.
We next performed title and abstract review of the identified articles. In keeping with the
scope of the recommendations, all studies that did not explicitly address any
pharmacotherapeutic clinical outcomes of the medications of interest were excluded (e.g.,
radiographic descriptive studies, pharmacokinetics, genomics, etc.). Because of the
relatively small number of identified articles, we included uncontrolled studies, regardless of
the number of patients reported. Review articles were excluded. Two reviewers (KR, RF)
reviewed all of the abstracts for inclusion, blinded to each other’s determinations.
Disagreement was resolved by a third reviewer (ST-R) and confirmed by a fourth reviewer
(TB), when necessary. Following title and abstract review, 239 articles remained for
consideration.
Each of the full-length articles was abstracted by one of a team of reviewers (SC, RF, AJ,
PN, NMP, KR, ST-R, or TB), with key elements from each article entered into an electronic
database. Articles were excluded during the full-length article review when no
pharmacotherapeutic clinical outcomes of medications of interest were identified; all of
these exclusions were verified by a second reviewer (TB). As a result, 214 articles were
included in the final comprehensive evidence report that was presented to the TFP prior to
the first round of voting.
An identical literature search was repeated on October 5, 2009, to identify any new
publications since the first systematic review. Thirty new articles were identified and
subjected to the same review process as the initial search. Seven fully abstracted articles
were added to the updated evidence report and presented to the TFP prior to the face-to-face
meeting.
Scenario definitions
In order to develop clinical scenarios in accordance with the RAND/UCLA Appropriateness
Method (18), several key clinical decision parameters were deemed necessary by the CEP:
disease phenotype, prognostic features, disease activity, and current therapy. Definitions and
values for these key parameters were as evidence based as possible and were determined
using a structured iterative process via electronic mail with repeated revisions to the
proposed parameters until they were accepted by all CEP members.
JIA treatment groups
Chronic childhood arthritis is a heterogeneous condition. The most recent ILAR disease
classification criteria (1) divide JIA into 6 distinct categories. However, this disease
classification system was not strictly applied to the development of these recommendations
for two reasons: currently, there is minimal evidence to support the differential treatment of
children with JIA for many of the category distinctions, and the inclusion of all 6 categories
would unnecessarily increase the total number of scenarios to an unmanageable number for
consideration by the TFP (18).
In place of the ILAR JIA classification, the CEP developed “treatment groups” for these
recommendations with the goal of succinctly representing clinical decision making in the
treatment of JIA. The JIA category of systemic arthritis proved to be especially challenging
to evaluate. Attempts to exhaustively depict the myriad possible clinical presentations of
systemic arthritis were impractical. Therefore, recommendations for the treatment of
significant active systemic features (e.g., fever) and active arthritis for patients with systemic
arthritis were considered separately and independently by the TFP. Other authors have
BEUKELMAN et al. Page 4













suggested this dichotomy when considering therapeutic choices for systemic arthritis (22).
The appropriate treatment of systemic arthritis patients with concurrently active systemic
features and active arthritis may be expected to incorporate elements of both sets of
recommendations, but this was not explicitly considered by the TFP. The 5 JIA treatment
groups used in these recommendations are described below.
History of arthritis of 4 or fewer joints—This group includes patients with the ILAR
categories of persistent oligoarthritis, as well as patients with psoriatic arthritis, enthesitis-
related arthritis, and undifferentiated arthritis who have developed active arthritis in only 4
or fewer joints in total throughout the history of their disease course. Patients who currently
have 4 or fewer active joints, but who have a history of 5 or more active joints in total, are
considered in the “history of arthritis of 5 or more joints” treatment group. Patients with
systemic arthritis or active sacroiliac arthritis are considered in separate treatment groups.
History of arthritis of 5 or more joints—This group includes patients with the ILAR
categories of extended oligoarthritis, rheumatoid factor (RF)---negative polyarthritis, RF-
positive polyarthritis, as well as patients with psoriatic arthritis, enthesitis-related arthritis,
and undifferentiated arthritis who have developed active arthritis in 5 or more joints in total
throughout the history of their disease. Patients in this group need not currently have 5 or
more active joints. Patients with systemic arthritis or active sacroiliac arthritis are considered
in separate treatment groups.
Active sacroiliac arthritis—This group includes all patients with clinical and imaging
evidence of active sacroiliac arthritis. This group is anticipated to include primarily patients
with the ILAR categories of enthesitis-related arthritis and psoriatic arthritis, but may
include patients from any of the ILAR JIA categories.
Systemic arthritis with active systemic features (and without active arthritis)—
This group includes all patients who fulfill the ILAR criteria for systemic arthritis and who
have active fever of systemic JIA with or without other systemic features, but without active
arthritis. An example of this clinical phenotype would be a patient whose arthritis resolved
spontaneously or rapidly upon initiation of NSAIDs but who had persistent fever.
Systemic arthritis with active arthritis (and without active systemic features)—
This category includes all patients who fulfill the ILAR criteria for systemic arthritis and
who have active arthritis, but without active systemic features. An example of this clinical
phenotype would be a patient whose systemic features resolved spontaneously or rapidly
upon initiation of NSAIDs but whose arthritis remained active.
Features of poor prognosis
Risk stratification is crucial for guiding optimal treatment. The prognosis for patients with
JIA is variable, and some clinical factors have been shown to predict worse outcomes. The
CEP considered the published literature and their personal clinical experience in developing
the features of poor prognosis for these recommendations.
Each JIA treatment group has its own respective features of poor prognosis. In each case, the
presence of one listed feature is sufficient to classify the patient as having a poor prognosis
for the purposes of these recommendations. A more complex approach to features of poor
prognosis would have increased the number of scenarios to an unmanageable number for
consideration by the TFP (18). The features of poor prognosis (and their corresponding
literature references) are listed according to each JIA treatment group in Tables 1---5. Of
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note, the CEP believed there was insufficient published evidence available to include
damage detected by imaging other than radiographs as a feature of poor prognosis in JIA.
JIA disease activity
Recommendations require clear definitions of disease activity to make rational therapeutic
choices. In these recommendations, “active joints” and “active arthritis” are defined by
joints with swelling not due to deformity or joints with limitation of motion and with pain or
tenderness (10). “Active fever” means current fever that is attributable to systemic arthritis
disease activity. At least one continuous measure of JIA disease activity has been recently
developed (39). Nevertheless, currently no continuous disease activity measures have been
extensively validated or widely applied to daily clinical practice. Accordingly, the CEP
developed levels of disease activity for these recommendations that are specific to each
treatment group and with the goal of succinctly capturing clinical decision making. It should
be noted that these disease activity levels are subjective and not strictly evidence based.
However, the creation of discrete disease activity levels was requisite for the effective use of
the RAND/UCLA Appropriateness Method.
These recommendations are based on 3 disease activity levels: low, moderate, and high.
Patients with inactive disease were not considered. In a broad sense, the low disease activity
level is meant to represent patients at the lowest disease activity level for which a majority
of clinicians may consider altering the current medication regimen, and the high disease
activity level is meant to represent patients with disease activity that is equivalent to or
higher than the “average” subject that may have been enrolled in a clinical trial of the
medications under consideration. The CEP considered baseline patient data from recently
published clinical trials (10,15,17,40---42), data from a recent attempt to define minimal
disease activity in JIA (43), and their personal clinical experience in developing the disease
activity levels for these recommendations. The disease activity levels are listed according to
each JIA treatment group in Tables 1---5.
During the evaluation of the clinical scenarios, TFP members were allowed to recommend
continuation of current therapy (not initiate a new therapeutic agent), regardless of the
current disease activity level. In addition to a patient’s current disease activity level,
clinicians in practice may consider a patient’s disease activity level prior to initiating the
current treatment regimen when evaluating the effectiveness of the current treatment. That
is, a current state of low disease activity may represent a recent major improvement for one
patient and no improvement for another. Due to the complexity and number of clinical
scenarios, previous disease activity levels were not included in the recommendation process
and TFP members considered the appropriateness of initiating new therapeutic agents based
on a patient’s current disease activity level only.
Therapeutic agent definitions
Medication classes used in the recommendation scenarios are defined as follows: NSAID
refers to all nonsteroidal antiinflammatory drugs used commonly in clinical practice in the
US and includes selective cyclooxygenase 2 inhibitors but not aspirin. Calcineurin inhibitors
refer to cyclosporine and tacrolimus. Tumor necrosis factor α (TNFα) inhibitors refer to
adalimumab, etanercept, and infliximab.
Clinical evaluation of the effectiveness of a given therapeutic agent may depend on the dose
received. For all recommendations, it is assumed that patients have received the maximum
tolerated typical dose of prior medications, as listed in Supplementary Appendix B
(available in the online version of this article at
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658). Of note, the dose of
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methotrexate was assumed to be 15 mg/m2 (0.6 mg/kg) and administered via the parenteral
route. These specific doses were used as a guide for TFP members when considering the
scenarios; higher doses of these therapeutic agents may be appropriate in some clinical
situations.
Clinical evaluation of the effectiveness of a given therapeutic agent may depend on the
duration of therapy. Some scenarios explicitly stated the duration of the current treatment
regimen. In scenarios where duration of therapy was not defined, it was assumed that the
duration of therapy was sufficiently long to assess the response to therapy.
The recommendations assume that all medication regimens may contain a single NSAID as
adjunct therapy when considering the appropriateness of initiating new therapies. For
example, a patient described as currently receiving methotrexate is assumed to be taking
methotrexate with concurrent use of a single NSAID, as appropriate.
Many of the recommendations refer to “initiating” a new therapy for patients presently
undergoing treatment for JIA. In these cases, “initiating” is defined as either adding the new
therapy while continuing current therapy or switching to the new therapy while
discontinuing the current therapy. To limit the total number of scenarios, we made no
distinction between adding and switching for some of the recommendations. Of note,
combination biologic DMARD therapy was not considered by these recommendations,
owing to concern from the reported increased incidence of infections in studies of
rheumatoid arthritis in adult populations (44,45). Accordingly, initiation of a new biologic
DMARD is always intended to be accompanied by discontinuation of any current biologic
DMARD.
Safety monitoring
Scenarios were created to evaluate the appropriateness of several safety monitoring
interventions for selected therapeutic agents and were voted upon by the TFP in the same
manner as the treatment scenarios.
RAND/UCLA Appropriateness Method voting and scoring
A teleconference was conducted to orient all TFP members to the voting task. Individual
scenarios contained an explicit question that incorporated the key clinical parameters
described above (e.g., “Rate the appropriateness of initiating TNFα inhibitor in a patient
with a history of arthritis of 5 or more joints who has received methotrexate for 6 months
and has moderate disease activity and features of poor prognosis”). There were 1,539 such
individual scenarios and each TFP member evaluated all of them.
Each scenario was evaluated for “appropriateness,” which is defined as “the health benefits
exceed the health risks by a sufficiently wide margin that the intervention is worth doing”
(18). In this evaluation, the risks of initiating a particular therapeutic agent include the risk
of not initiating an alternative agent (e.g., the risk of initiating NSAID monotherapy includes
the risk of not initiating methotrexate with its greater potential for therapeutic benefit). The
TFP scored each scenario on a 9-point scale, with scores of 7---9 denoting “appropriate,”
1---3 denoting “inappropriate,” and 4---6 denoting “uncertain,” i.e., either the risks and
benefits are approximately equal or not enough information is available to make a
meaningful evaluation. TFP members cast their votes while taking into account the currently
available published literature (including but not limited to that provided to them in the
evidence report) and their own personal clinical experience. Votes were cast independently
by entering them into a formatted electronic spread sheet. The voting sheets were then
electronically collected and combined to analyze the results.
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The votes were analyzed in accordance with the RAND/UCLA Appropriateness Method
(18), taking into account both the distribution and the median value of the votes. The
scenario votes were first evaluated for disagreement (wide dispersion of votes), defined as
one-third or more of the TFP assigning a score of inappropriate (1, 2, or 3), while one-third
or more of the TFP assigned the same scenario a score of appropriate (7, 8, or 9). In the
absence of disagreement, a median score of 3 or less classified a scenario as “inappropriate,”
and a median rating of 7 or greater classified a scenario as “appropriate.” Those scenarios
with median ratings in the 3.5 to 6.5 range, together with those where disagreement
occurred, were classified as “uncertain.”
Following analysis of the first round of voting, a subsequent face-to-face meeting of the TFP
was conducted and discussion was focused on scenarios where the voting outcome was
“uncertain.” Following sufficient discussion on each group of scenarios, the TFP members
voted for the final time. No attempts were made to “force” consensus among the TFP.
Rather, the RAND/UCLA Appropriateness Method largely seeks to identify existing
consensus (18).
Developing recommendations from votes
Statements listed as recommendations met the RAND/UCLA Appropriateness Method
criteria for “appropriate” in the final TFP votes with no wide dispersion of votes, and the
median score was in the appropriate range (7 to 9). In some instances, more than one
individual therapeutic agent was recommended for a given combination of clinical
parameters; these are noted as being “recommended as one treatment approach.” Indications
for initiating therapeutic agents that did not meet the criteria for appropriate were
summarized as either uncertain or inappropriate. In these summary statements, uncertain
means that some or all of the scenarios met the definition of “uncertain” and some or none
of the scenarios met the definition of “inappropriate.” Inappropriate means that all of the
scenarios met the definition of “inappropriate” and none met the definition of “uncertain.”
The recommendations were reviewed in detail by all CEP members to ensure proper and
clear translation of the TFP votes into text.
During the face-to-face discussion of the scenarios, several points were raised that the TFP
members believed should be mentioned in the recommendations, even though they were not
addressed in the voting scenarios. Following discussion, consensus on these points was
reached through a simple show of hands vote. These statements are clearly noted in the
results, are not considered formal recommendations, and were not assigned a level of
evidence.
Rating evidence for recommendations
For each final recommendation of appropriate or inappropriate, a level of evidence was
assigned based on the methods of the University of Oxford Centre for Evidence-Based
Medicine, UK (46). This categorization of evidence was used in the recently published
European League Against Rheumatism recommendations for the management of rheumatoid
arthritis (47) and incorporates the concept of “extrapolations,” where published data are used
in a situation that has potentially clinically important differences from the original study
situation. Such situations are frequently encountered when the patient’s clinical factors in a
recommendation do not match exactly with those of the supporting studies (19). The Oxford
system also distinguishes between recommendations for which there is low-grade evidence
and those for which there is an absence of published evidence.
Level of evidence “A” was assigned when the recommendation was supported by
randomized clinical trials (or consistent inception cohort studies for questions of prognosis).
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Level of evidence “B” was assigned when the recommendation was supported by
nonrandomized controlled studies (e.g., cohort and case---control studies) or extrapolations
from randomized clinical trials. Level of evidence “C” was assigned when the
recommendation was supported by uncontrolled studies (case series), extrapolations from
nonrandomized controlled studies, or marked extrapolations from randomized clinical trials
(e.g., studies of adult arthritis patients applied to juvenile arthritis or studies of polyarthritis
phenotype applied to oligoarthritis). Level of evidence “D” was assigned when the
recommendation was based on expert opinion without supporting published evidence.
Managing perceived potential conflicts of interest
Perceived potential conflicts of interest were managed in a prospective and structured
manner. All members of the CEP and TFP completed and submitted the ACR disclosure of
interest form prior to participation in the project. The forms were updated prior to the face-
to-face meeting. A summary listing of all perceived potential conflicts of interest was
distributed to all project participants and was submitted for publication along with these
recommendations.
Peer review of recommendations
Following submission of the draft recommendations, the ACR invited peer review by
members of the ACR Practice Guidelines Subcommittee, the ACR Quality of Care
Committee, and the ACR Board of Directors. The recommendations were ultimately subject
to the regular review process of this journal.
Updates to ACR recommendations
We expect that knowledge of the appropriate therapeutic management of JIA will continue
to advance. Clearly, these ACR recommendations will require updating to remain accurate
and relevant. We suggest that approximately 3 years after the initiation of this current
project (i.e., in 2012), the ACR Practice Guidelines Subcommittee and the ACR Quality of
Care Committee evaluate newly published evidence and solicit expert opinion on the need
for revision of these recommendations. Targeted updates focused only on areas of new
published evidence may be appropriate.
Future research in the treatment of JIA may reasonably be directed by knowledge
deficiencies identified by these recommendations. Of particular note to the CEP was the
need for comparative long-term studies of the benefits and risks of early initiation of
biologic therapies, development and implementation of continuous disease activity scores in
clinical practice, studies of the evaluation and management of enthesitis, studies of the
management of systemic arthritis and macrophage activation syndrome, and studies of the
appropriate management of patients with inactive disease receiving therapy.
RESULTS
Each ACR recommendation for the treatment of JIA is followed by the assigned level of
evidence and the corresponding publication citations.
General medication usage
The TFP considered the general usage of intraarticular glucocorticoid injections and the use
of methotrexate when initiating TNFα inhibitors. These recommendations apply broadly
across treatment groups.
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Glucocorticoid joint injections—The use of glucocorticoid joint injections for active
arthritis was recommended, regardless of concurrent therapy (no DMARD, nonbiologic
DMARD, or biologic DMARD) or JIA treatment group (level C) (48---65). Glucocorticoid
joint injections should be performed with triamcinolone hexacetonide, owing to its
demonstrated superior efficacy (level A) (52,53). Intraarticular glucocorticoid injections are
expected to result in clinical improvement of arthritis for at least 4 months (level A)
(49---66). A shorter duration of clinical response may imply a need for escalation of
systemic therapy. Intraarticular glucocorticoid injections that result in clinical improvement
of arthritis for at least 4 months may be repeated as needed (level B) (50,53,57,64,65).
Methotrexate with TNFα inhibitors—Continuing methotrexate when initiating a TNFα
inhibitor (etanercept or adalimumab) was recommended for patients who had a partial
previous clinical response to methotrexate (level B) (67). The TFP did not reach agreement
on continuing or discontinuing methotrexate when initiating a TNFα inhibitor (etanercept or
adalimumab) for patients who had a poor previous clinical response to methotrexate. The
appropriateness of continuing methotrexate when initiating infliximab was assumed and was
not evaluated by the TFP, owing to the recognized potential for methotrexate to reduce the
incidence of neutralizing antibodies to infliximab (68) and consistent with the labeling of
infliximab (69).
Initiation of therapeutic agents
The appropriateness of initiating various therapeutic agents in the treatment of JIA is
organized by treatment group. Each recommendation is characterized by the patient’s
clinical factors: treatment group, current medication, disease activity, and features of poor
prognosis. Individual therapeutic agents are listed in the order of escalation of therapy as
determined by the TFP. In situations where two or more agents were recommended for
similar patient clinical factors, the agents are listed alphabetically. The recommendations are
not mutually exclusive, i.e., the initiation of more than one therapeutic agent may be
appropriate for a given set of patient clinical factors due to overlapping indications.
Therapeutic agents that were considered by the TFP but not recommended for initiation are
listed at the end of each treatment group in alphabetical order.
History of arthritis of 4 or fewer joints
The definitions of disease activity and features of poor prognosis for this treatment group are
listed in Table 1. A diagram of the overall treatment strategy is shown in Figure 1.
NSAID monotherapy—Initiation of NSAID monotherapy (without glucocorticoid joint
injection) was recommended as one treatment approach for patients with low disease
activity, without joint contracture, and without features of poor prognosis (level B)
(70---76). Continuation of NSAID monotherapy (without additional therapy) for longer than
2 months was inappropriate for patients with active arthritis, irrespective of poor prognostic
features.
Intraarticular glucocorticoid injections—Intraarticular glucocorticoid injections (with
or without additional therapy) were recommended for all patients with active arthritis,
irrespective of disease activity level, prognostic features, or joint contracture (level C)
(48---66). As stated above, glucocorticoid joint injections should be performed with
triamcinolone hexacetonide (level A) (52) and are expected to result in clinical improvement
of arthritis for at least 4 months (level A) (49---66). A shorter duration of clinical
improvement may imply a need for escalation of systemic therapy. Glucocorticoid injections
that result in clinical improvement of arthritis for at least 4 months may be repeated as
needed (level B) (50,53,57,64,65).
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Methotrexate—Initiation of methotrexate was recommended as initial treatment (without
prior therapy) for patients with high disease activity and features of poor prognosis (level C)
(40,77---83). Following initial glucocorticoid joint injection(s), initiation of methotrexate
was recommended for patients with high disease activity without features of poor prognosis
and for patients with moderate disease activity and features of poor prognosis (level C)
(40,77---83). Following repeated glucocorticoid injections, initiation of methotrexate was
recommended for patients with moderate disease activity without features of poor prognosis
and for patients with low disease activity and features of poor prognosis (level C)
(40,77---83).
Sulfasalazine—Initiation of sulfasalazine was recommended following glucocorticoid
joint injection or an adequate trial of NSAIDs for patients with the enthesitis-related arthritis
category of JIA with moderate or high disease activity, irrespective of features of poor
prognosis (level B) (84). Initiation of sulfasalazine was uncertain for patients who are not
diagnosed with the enthesitis-related arthritis category of JIA.
TNFα inhibitors—Initiation of a TNFα inhibitor was recommended for patients who have
received glucocorticoid joint injections and 3 months of methotrexate at the maximum
tolerated typical dose and have moderate or high disease activity and features of poor
prognosis (level C) (10,15). Initiation of a TNFα inhibitor was also recommended for
patients who have received glucocorticoid joint injections and 6 months of methotrexate and
have high disease activity without features of poor prognosis (level C) (10,15).
Additionally, initiation of a TNFα inhibitor was recommended for patients specifically with
the enthesitis-related arthritis category of JIA who have received glucocorticoid joint
injections and an adequate trial of sulfasalazine (without prior methotrexate) and have
moderate or high disease activity, irrespective of prognostic features (level C) (11,85).
Abatacept—Initiation of abatacept was uncertain prior to initiation of a TNFα inhibitor.
Hydroxychloroquine—Initiation of hydroxychloroquine monotherapy (with or without
concurrent NSAIDs) was inappropriate for patients with active arthritis (level C) (86).
Leflunomide—Initiation of leflunomide was uncertain.
Nonbiologic DMARD combinations—Initiation of nonbiologic DMARD combinations
(methotrexate plus sulfasalazine and/or hydroxychloroquine) was uncertain.
History of arthritis of 5 or more joints
The definitions of disease activity and features of poor prognosis for this treatment group are
listed in Table 2. A diagram of the overall treatment strategy is shown in Figure 2.
NSAID monotherapy—Initiation of NSAID therapy alone (monotherapy without
glucocorticoid joint injection) was uncertain for patients with active arthritis. Continuation
of NSAID monotherapy for longer than 2 months was inappropriate for patients with active
arthritis, irrespective of poor prognostic features (level C) (80,87).
Methotrexate—Initiation of methotrexate was recommended as initial treatment for
patients with high disease activity, irrespective of poor prognostic factors, and for patients
with moderate disease activity and features of poor prognosis (level B) (40,77---80).
Following approximately 1 month of NSAIDs, initiation of methotrexate was recommended
for patients with low disease activity and features of poor prognosis (level B) (40,77---80).
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Following approximately 1 to 2 months of NSAIDs, initiation of methotrexate was
recommended for patients with moderate disease activity without features of poor prognosis
(level B) (40,77---80).
Leflunomide—The TFP generally favored the use of methotrexate over leflunomide,
owing to greater personal and collective experience with methotrexate. However, initiation
of leflunomide was recommended as one treatment approach as initial treatment for patients
with high disease activity and features of poor prognosis (level B) (77). Following a brief
trial of NSAIDs, initiation of leflunomide was recommended as one treatment approach for
patients with high disease activity without features of poor prognosis and for patients with
moderate disease activity with features of poor prognosis (level B) (77).
TNFα inhibitors—Initiation of a TNFα inhibitor was recommended for patients who have
received methotrexate or leflunomide for 3 months at the maximum tolerated typical dose
and have moderate or high disease activity, irrespective of poor prognostic features (level B)
(10,15). Initiation of a TNFα inhibitor was also recommended for patients who have
received methotrexate or leflunomide for 6 months and have low disease activity,
irrespective of poor prognostic features (level B) (10,15).
Switching from one TNFα inhibitor to another was recommended as one treatment approach
for patients who have received the current TNFα inhibitor for 4 months and have moderate
or high disease activity, irrespective of poor prognostic features (level C) (88,89). Switching
to a TNFα inhibitor was recommended as one treatment approach for patients who have
received abatacept for 3 months and have high disease activity and features of poor
prognosis and for patients who have received abatacept for 6 months and have moderate or
high disease activity, irrespective of prognostic features (level D).
Abatacept—Initiation of abatacept was recommended as one treatment approach for
patients who have received a TNFα inhibitor for 4 months and have high disease activity,
irrespective of features of poor prognosis, or moderate disease activity and features of poor
prognosis (level B) (17). Initiation of abatacept was recommended as one treatment
approach for patients who have received more than one TNFα inhibitor sequentially and
have moderate or high disease activity, irrespective of poor prognostic features, or low
disease activity with features of poor prognosis (level B) (17).
Rituximab—Initiation of rituximab was recommended as one treatment approach for
patients who have received a TNFα inhibitor and abatacept sequentially and have high
disease activity, irrespective of poor prognostic features, or have moderate disease activity
and features of poor prognosis (level C) (90---92). Although not formally assessed using the
RAND/UCLA Appropriateness Method, there was consensus among the TFP that rituximab
may be more appropriate for patients who test positive for RF compared to patients who do
not.
Anakinra—Initiation of anakinra was uncertain.
Hydroxychloroquine—Initiation of hydroxychloroquine monotherapy (with or without
concurrent NSAIDs) was inappropriate for patients with active arthritis (level A) (86).
Sulfasalazine—Initiation of sulfasalazine was uncertain. Patients with the enthesitis-
related arthritis category of JIA and history of arthritis of 5 or more joints were not
independently considered by the TFP.
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Nonbiologic DMARD combinations—Initiation of nonbiologic DMARD combinations
(methotrexate plus sulfasalazine and/or hydroxychloroquine) was uncertain. As stated in
Materials and Methods, intolerance of or contraindications to biologic DMARD therapies
were not considered by the TFP.
Active sacroiliac arthritis
As stated in Materials and Methods, active sacroiliac arthritis was defined by the presence of
clinical and imaging evidence. The definitions of disease activity and features of poor
prognosis for this treatment group are listed in Table 3. The only medication class evaluated
by the TFP for this treatment group was the TNFα inhibitors. There is no corresponding
figure for this treatment group.
TNFα inhibitors—In general, initiation of a TNFα inhibitor was recommended more
readily for patients with active sacroiliac arthritis than for patients without this joint
affected. Initiation of a TNFα inhibitor was recommended for patients with active sacroiliac
arthritis who have received an adequate trial of NSAIDs and have high disease activity and
features of poor prognosis (level C) (93,94). Initiation of a TNFα inhibitor was also
recommended for patients who have received 3 months of methotrexate and have high
disease activity, irrespective of prognostic factors, or moderate disease activity with features
of poor prognosis, or 6 months of methotrexate and moderate disease activity without
features of poor prognosis (level C) (93,94). Also recommended was initiation of a TNFα
inhibitor for patients who have received 3 months of sulfasalazine and have moderate or
high disease activity, irrespective of prognostic features, or 6 months of sulfasalazine and
low disease activity with features of poor prognosis (level C) (93,94).
Systemic arthritis
As noted in Materials and Methods, the JIA category of systemic arthritis was divided into
two treatment groups: active systemic features and active arthritis. The appropriate treatment
of patients with concurrent active systemic features and active arthritis may be expected to
incorporate elements of both sets of recommendations. Given the variable course of
systemic arthritis and the extent to which the prior disease course may influence subsequent
treatment decisions, the TFP evaluated the appropriateness of initiating therapies for
recently diagnosed patients, as opposed to patients with extensive and potentially influential
disease histories.
As noted in Materials and Methods, the initiation of treatment with interleukin-6 inhibitors
(such as tocilizumab) or interleukin-1 inhibitors other than anakinra (such as canakinumab
or rilonacept) was not considered in the development of these recommendations because
these therapeutic agents were not widely commercially available at the time. Options for the
treatment of systemic arthritis appear to be increasing. The appropriateness of initiating
recently available therapeutic agents for the treatment of systemic arthritis may need to be
the focus of a timely update to these recommendations.
Systemic arthritis with active systemic features (and without active arthritis)
The definitions of disease activity and features of poor prognosis for this treatment group are
listed in Table 4. A diagram of the overall treatment strategy is shown in Figure 3.
These recommendations are not meant to apply to patients with clinical and laboratory
evidence of macrophage activation syndrome that warrants specific modification of therapy.
Life-threatening clinical scenarios (e.g., cardiac tamponade) were not considered by the TFP
and may warrant deviation from these recommendations. TNFα inhibitors were not
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considered by the TFP in the treatment of active systemic features, owing to their reported
relatively poor effectiveness (12,89,95---98).
NSAID monotherapy—Although not formally assessed using the RAND/UCLA
Appropriateness Method, there was consensus among the TFP that the use of NSAID
monotherapy is appropriate during the clinical evaluation of possible systemic arthritis. The
following recommendations apply to patients who have been diagnosed with systemic
arthritis.
The initiation (or continuation) of NSAID monotherapy was uncertain for patients with
active fever. Initiation of NSAID monotherapy was inappropriate for patients with active
fever and physician global assessment of overall disease activity (MD global) of ≥7 of 10
(level D). Continuation of NSAID monotherapy for a duration greater than 1 month was
inappropriate for patients with active fever (level C) (99).
Systemic glucocorticoids—Owing to a near complete lack of published evidence,
specific systemic glucocorticoid doses or routes of administration were not considered by
the TFP.
Initiation of systemic glucocorticoids (with or without additional concurrent therapy) was
recommended as initial therapy for patients with active fever and MD global of ≥7 (level D).
Initiation of systemic glucocorticoids following up to 2 weeks of NSAIDs was
recommended for all patients with active fever (level C) (99,100).
Anakinra—Initiation of anakinra was recommended for all patients with active fever and
features of poor prognosis, irrespective of current therapy (level C) (101). Initiation of
anakinra was recommended for all patients who sustain or develop active fever while
receiving systemic glucocorticoids (level C) (16,101---103).
Calcineurin inhibitors—Initiation of calcineurin inhibitors for patients with active fever
and without active arthritis was uncertain for initial management.
Intravenous immunoglobulin—Initiation of intravenous immunoglobulin for patients
with active fever and without active arthritis was uncertain for initial management.
Methotrexate—Initiation of methotrexate was inappropriate for initial management of
patients with active fever and without active arthritis (level B) (78).
Thalidomide—Initiation of thalidomide for patients with active fever and without active
arthritis was uncertain for initial management.
Systemic arthritis with active arthritis (and without active systemic features)
The definitions of disease activity and features of poor prognosis for this treatment group are
listed in Table 5. A diagram of the overall treatment strategy is shown in Figure 4.
Consistent with the assessment of other treatment groups, the appropriateness of systemic
glucocorticoids for the treatment of arthritis in patients with systemic arthritis was not
addressed.
NSAID monotherapy—Initiation of NSAID monotherapy (with or without glucocorticoid
joint injections) was recommended for patients with low disease activity without features of
poor prognosis (level B) (70). It was presumed that most patients with newly diagnosed
systemic arthritis would have received NSAIDs during their diagnostic evaluation.
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Continuation of NSAID monotherapy (without systemic therapy) for a duration greater than
1 month was uncertain for patients with any level of disease activity, irrespective of poor
prognostic features (level D).
Methotrexate—Initiation of methotrexate was recommended for all patients with active
arthritis following 1 month or less of NSAID monotherapy (with or without glucocorticoid
joint injections), irrespective of poor prognostic features (level B) (40,79).
Anakinra—Initiation (addition) of anakinra was recommended for patients who have
received methotrexate and who have moderate or high disease activity, irrespective of
features of poor prognosis (level C) (16,101---104). Initiation of anakinra was also
recommended for patients who have received methotrexate and a TNFα inhibitor or
methotrexate and abatacept and have high or moderate disease activity, irrespective of poor
prognostic factors (level C) (16,101---103). Although not formally assessed using the
RAND/UCLA Appropriateness Method, there was consensus among the TFP that initiation
of anakinra for the treatment of arthritis may be less appropriate later in the disease course
compared to nearer to the onset of disease.
TNFα inhibitor—Initiation (addition) of a TNFα inhibitor was recommended for patients
who have received 3 months of methotrexate and have moderate or high disease activity,
irrespective of features of poor prognosis (level B) (10,15). The TFP expressed that it may
be appropriate to switch therapy from anakinra to a TNFα inhibitor for patients with
moderate or high disease activity, irrespective of features of poor prognosis (level D).
However, concern was expressed regarding possible unmasking of latent systemic disease
activity when discontinuing anakinra.
Abatacept—Initiation of abatacept was recommended for patients who have received
methotrexate and a TNFα inhibitor and have high disease activity, irrespective of features of
poor prognosis, or have moderate disease activity and poor prognostic features (level B)
(17).
Calcineurin inhibitors—Initiation of calcineurin inhibitors was inappropriate for patients
with active arthritis and without active systemic features (level C) (105,106).
Safety monitoring
The TFP evaluated the appropriateness of several safety monitoring interventions by
considering the health benefits (minimizing the chance of toxicity or adverse events) and
harms (frequent phlebotomies, false-positive test results). As with the evaluation of initiation
of therapeutic agents, the TFP did not consider the economic costs of monitoring or adverse
events.
NSAID monitoring—Measurement of serum creatinine, urinalysis, complete blood cell
count, and liver enzymes was recommended prior to or soon after the initiation of treatment
with routine NSAIDs (level D). Periodic repeat measurements of serum creatinine,
urinalysis, complete blood cell count, and liver enzymes were recommended approximately
twice yearly for patients receiving chronic daily NSAIDs and approximately once yearly for
patients receiving NSAIDs routinely (e.g., 3 to 4 days per week) (level D).
Methotrexate monitoring—Measurement of serum creatinine, complete cell blood
count, and liver enzymes was recommended prior to initiation of methotrexate (level D).
Shortly after initiation of methotrexate, repeat measurements of serum creatinine, complete
blood cell count, and liver enzymes were recommended. No single preferred monitoring
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strategy was recommended. In general, the TFP recommended laboratory measurements
approximately 1 month after initiating methotrexate and then approximately 1 to 2 months
after any subsequent increase in methotrexate dose (level D). Repeat measurements of serum
creatinine, complete blood cell count, and liver enzymes were recommended approximately
every 3 to 4 months for patients receiving a stable dose of methotrexate with no recent
history of abnormal laboratory monitoring results (level C) (107,108). Although not
formally evaluated using the RAND/UCLA Appropriateness Method, there was consensus
among the TFP that laboratory measurements be obtained 1 to 2 days prior to the scheduled
weekly dose of methotrexate.
The TFP made several recommendations about appropriate responses to elevated liver
enzymes for patients receiving methotrexate. In response to liver enzyme elevation of as
much as 2 times the upper limit of normal, either no specific action or rechecking liver
enzymes at a shorter interval was recommended. In response to liver enzyme elevation more
than 2 times the upper limit of normal, decreasing the dose of methotrexate or temporarily
withholding methotrexate administration was recommended. If liver enzymes remain at
levels more than 3 times the upper limit of normal following a decrease in the methotrexate
dose, discontinuation of methotrexate was recommended (all recommendations are level C)
(107---110).
TNFα inhibitor monitoring—Measurement of complete blood cell count, liver enzymes,
and serum creatinine was recommended prior to initiation of TNFα inhibitors and
approximately every 3 to 6 months thereafter for patients who continue to receive TNFα
inhibitors (level D).
Tuberculosis screening—Obtaining Mantoux purified protein derivative skin testing for
tuberculosis was recommended prior to initiation of TNFα inhibitors for all patients (level
C) (111). Repeat testing approximately once yearly thereafter was recommended for all
patients who continue to receive TNFα inhibitors (level D). The appropriateness of
interferon-γ release assays for detecting tuberculosis was not evaluated. The appropriateness
of tuberculosis testing prior to the initiation of biologic agents other than TNFα inhibitors
was not evaluated.
Hepatitis B and hepatitis C screening—Antibody testing for infection with hepatitis B
or hepatitis C prior to initiating methotrexate or TNFα inhibitors was recommended for
patients with risk factors for infection (level D). Risk factors for hepatitis B and hepatitis C
infections are shown in Supplementary Appendix C (available in the online version of this
article at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658).
DISCUSSION
Following a systematic review of the literature and using a formal group assessment process,
we provide evidence and consensus-based recommendations for the appropriate initiation
and safety monitoring of therapeutic agents in the treatment of JIA. These recommendations
are meant as a guide to health care providers caring for children with JIA and are not meant
to take the place of individualized care or to serve as health care coverage guidelines. These
recommendations will require future updates as scientific knowledge expands regarding the
benefits and risks of the treatment of JIA.
Addendum
Therapies that were approved after the original literature review are not included in these
recommendations.
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Treatment recommendations for patients with a history of arthritis of 4 or fewer joints.
These recommendations are intended for patients with juvenile idiopathic arthritis (JIA) who
have only developed active arthritis in 4 or fewer joints in total throughout the history of
their disease course and are based upon duration of current therapy, disease activity, and
features of poor prognosis. If criteria for escalation of therapy are not met, then continue
current therapy along with adjunct nonsteroidal antiinflammatory drugs (NSAIDs) or
glucocorticoid joint injections, as needed. Recommendations for reduction of therapy are not
addressed. See Table 1 for definitions of disease activity and features of poor prognosis. * =
sulfasalazine may be an appropriate treatment for patients with the enthesitis-related arthritis
category of JIA (see text for details); MTX = methotrexate; TNFα = tumor necrosis factor α.
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Treatment recommendations for patients with a history of arthritis of 5 or more joints. These
recommendations are intended for patients with juvenile idiopathic arthritis who have
developed active arthritis in 5 or more joints in total throughout the history of their disease
and are based upon duration of current therapy, disease activity, and features of poor
prognosis. If criteria for escalation of therapy are not met, then continue current therapy
along with adjunct nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoid joint
injections, as needed. Recommendations for reduction of therapy are not addressed. See
Table 2 for definitions of disease activity and features of poor prognosis. * = leflunomide
may be an appropriate treatment alternative (see text for details); MTX = methotrexate;
TNFα = tumor necrosis factor α.
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Treatment recommendations for patients with systemic arthritis and active systemic features
(and without active arthritis). These recommendations are intended for patients with juvenile
idiopathic arthritis who have systemic arthritis with active systemic features and without
active arthritis. Recommendations are based upon duration of current therapy, disease
activity, and features of poor prognosis. If criteria for escalation of therapy are not met, then
continue current therapy along with adjunct nonsteroidal antiinflammatory drugs (NSAIDs),
as needed. Recommendations for reduction of therapy are not addressed. See Table 4 for
definitions of disease activity and features of poor prognosis. MD Global = physician global
assessment of overall disease activity (range 0---10).
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Treatment recommendations for patients with systemic arthritis and active arthritis (and
without active systemic features). These recommendations are intended for patients with
juvenile idiopathic arthritis who have systemic arthritis with active arthritis and without
active systemic features. Recommendations are based upon duration of current therapy,
disease activity, and features of poor prognosis. If criteria for escalation of therapy are not
met, then continue current therapy along with adjunct nonsteroidal antiinflammatory drugs
(NSAIDs), as needed. Recommendations for reduction of therapy are not addressed. See
Table 5 for definitions of disease activity and features of poor prognosis. MTX =
methotrexate; TFNα = tumor necrosis factor α; * = initiation of anakinra for the treatment of
arthritis may be less appropriate later in the disease course compared to nearer the onset of
disease; † = switching from anakinra to a TNFα inhibitor may be appropriate for some
patients with moderate or high disease activity, irrespective of features of poor prognosis,
but there is a possible risk of unmasking latent systemic features when discontinuing
anakinra.
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Table 1
Features of poor prognosis and disease activity for a history of arthritis of 4 or fewer joints
Features of poor prognosis (must satisfy 1)
 Arthritis of the hip (23---25) or cervical spine
 Arthritis of the ankle (25---27) or wrist (26,28) AND marked (29) or prolonged (23,25,26,29,30) inflammatory marker elevation
 Radiographic damage (erosions or joint space narrowing by radiograph) (31)
Disease activity levels
 Low disease activity (must satisfy all)
  1 or fewer active joints
  Erythrocyte sedimentation rate or C-reactive protein level normal
  Physician global assessment of overall disease activity <3 of 10
  Patient/parent global assessment of overall well-being <2 of 10
 Moderate disease activity (does not satisfy criteria for low or high activity)
  1 or more features greater than low disease activity level AND fewer than 3 features of high disease activity
 High disease activity (must satisfy at least 3)
  2 or more active joints
  Erythrocyte sedimentation rate or C-reactive protein level greater than twice upper limit of normal
  Physician global assessment of overall disease activity ≥7 of 10
  Patient/parent global assessment of overall well-being ≥4 of 10
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Table 2
Features of poor prognosis and disease activity for a history of arthritis of 5 or more joints
Features of poor prognosis (must satisfy 1)
 Arthritis of the hip (23---25) or cervical spine
 Positive rheumatoid factor (5,23,28,30,32,33) OR anti---cyclic citrullinated peptide (33,34) antibodies
 Radiographic damage (erosions or joint space narrowing by radiograph) (31)
Disease activity levels
 Low disease activity (must satisfy all)
  4 or fewer active joints
  Erythrocyte sedimentation rate or C-reactive protein level normal
  Physician global assessment of overall disease activity <4 of 10
  Patient/parent global assessment of overall well-being <2 of 10
 Moderate disease activity (does not satisfy criteria for low or high activity)
  1 or more features greater than low disease activity level AND fewer than 3 features of high disease activity
 High disease activity (must satisfy at least 3)
  8 or more active joints
  Erythrocyte sedimentation rate or C-reactive protein level greater than twice upper limit of normal
  Physician global assessment of overall disease activity ≥7 of 10
  Patient/parent global assessment of overall well-being ≥5 of 10
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Table 3
Feature of poor prognosis and disease activity for active sacroiliac arthritis
Feature of poor prognosis
 Radiographic damage of any joint (erosions or joint space narrowing by radiograph)
Disease activity levels
 Low disease activity (must satisfy all)
  Normal back flexion
  Erythrocyte sedimentation rate or C-reactive protein level normal
  Physician global assessment of overall disease activity <4 of 10
  Patient/parent global assessment of overall well-being <2 of 10
 Moderate disease activity (does not satisfy criteria for low or high activity)
  1 or more features greater than low disease activity level AND fewer than 2 features of high disease activity
 High disease activity (must satisfy at least 2)
  Erythrocyte sedimentation rate or C-reactive protein greater than twice upper limit of normal
  Physician global assessment of overall disease activity ≥7 of 10
  Patient/parent global assessment of overall well-being ≥4 of 10
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Table 4
Features of poor prognosis and disease activity for systemic arthritis with active systemic features (and
without active arthritis)
Features of poor prognosis
 6-month duration of significant active systemic disease, defined by: fever (35---37), elevated inflammatory markers (35---37), or requirement
for treatment with systemic glucocorticoids (36)
Disease activity levels (2 levels)
 Active fever AND physician global assessment of overall disease activity <7 of 10
 Active fever AND systemic features of high disease activity (e.g., significant serositis) that result in physician global assessment of overall
disease activity ≥7 of 10













BEUKELMAN et al. Page 33
Table 5
Features of poor prognosis and disease activity for systemic arthritis with active arthritis (and without active
systemic features)
Features of poor prognosis (must satisfy 1)
 Arthritis of the hip (38)
 Radiographic damage (erosions or joint space narrowing by radiograph) (31)
Disease activity levels
 Low disease activity (must satisfy all)
  4 or fewer active joints
  Erythrocyte sedimentation rate or C- reactive protein level normal
  Physician global assessment of overall disease activity <4 of 10
  Patient/parent global assessment of overall well-being <2 of 10
 Moderate disease activity (does not satisfy criteria for low or high activity)
  1 or more features greater than low disease activity level AND fewer than 3 features of high disease activity
 High disease activity (must satisfy at least 3)
  8 or more active joints
  Erythrocyte sedimentation rate or C- reactive protein level greater than twice upper limit of normal
  Physician global assessment of overall disease activity ≥7 of 10
  Patient/parent global assessment of overall well-being ≥5 of 10
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Table 6
Summary of recommendations for medication safety monitoring
Nonsteroidal antiinflammatory drugs
 Complete blood cell count, liver enzymes, serum creatinine
  Prior to or soon after initiation of routine use
  Repeat approximately twice yearly for chronic daily use
  Repeat approximately once yearly for routine use (3---4 days per week)
Methotrexate
 Complete blood cell count, liver enzymes, serum creatinine
  Prior to initiation
  Approximately 1 month after initiation
  Approximately 1---2 months after increase in dose
  Repeat approximately every 3---4 months if prior results normal and dose stable
Tumor necrosis factor α inhibitors
 Complete blood cell count, liver enzymes, serum creatinine
  Prior to initiation
  Repeat approximately every 3---6 months
 Tuberculosis screening
  Prior to initiation
  Repeat approximately once yearly
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